With an increasingly complex M&A landscape likely to endure beyond 2020, dealmakers will need to navigate multiple challenges – from a slowing global economy, regulatory demands, evolving workforces and geopolitical strains. Whether executing deals closer to home or embarking on a bold strategy abroad, you benefit from a trusted advisor with a deep grasp of all the issues and the creative flair to add value to your business.
As a “standout Israeli practice,” Tulchinsky’s M&A department provides clients with “a consistently strong and dedicated team” that is particularly renowned for its vast experience across the full spectrum, including in the hi-tech, life sciences and pharmaceutical industries. From developing a strategy, leading negotiations, and carrying out due diligence, to closing financing and executing, we have a proven track record in providing sound, astute advice that has earned us key roles in landmark transactions for major domestic corporations and multinationals.
Such highlights include Teva’s USD 40.5 billion acquisition of Allergan’s generic business; Orbotech’s USD 3.4 billion acquisition by KLA; and the USD 4.8 billion merger of Chromatis Networks into Lucent – at the time the largest “exit” ever to take place in Israel.
Tapping into the extensive legal, commercial, and financial background of our team, we combine the highest levels of professional integrity and excellence with a tailored and detailed approach to each client’s objectives, ensuring no stone is left unturned as they seek to seize the opportunities that come their way.